Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Diagnosis/Condition for Entry into the Trial Phase 1 - Presence of histologically confirmed malignancy that has progressed following at least one therapy and able to be visualized on imaging. Measurable disease is not required. Patients with known targetable mutations must have progressive disease on the appropriated targeted drug therapy. Phase 2 - Presence of MRP colon cancer that has progressed following at least two lines of therapy. Ten patients will be included who have disease that can be biopsied pre- and post-therapy. Inclusion Criteria: * Be willing and able to provide written informed consent for the trial * Have measurable disease based on RECIST 1.1 (Phase 2) * Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion * Have a performance status of 0 or 1 on the ECOG Performance Scale * Have adequate organ function, according to screening labs performed within 10 days of treatment initiation * Subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication Exclusion Criteria: * Currently participating/previously participated in a therapeutic study and received study therapy or used an investigational device within 4 weeks of the first dose of treatment * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first …